Shots:

• The US FDA has approved Agile’s non-daily- non-invasive contraceptive- Twirla for contraception in women with BMI is <30 kg/m2 and for whom a combined hormonal contraceptive is appropriate
• The transdermal system must be applied weekly to the abdomen- buttock- or upper torso (Ex- breast) to deliver a 30mcg daily dose of ethinyl estradiol and 120mcg daily dose of levonorgestrel
• The approval requires the company to conduct a post-marketing study to assess risks for venous thromboembolism and arterial thromboembolism in new users of the contraception compared with new users of other combined hormonal contraceptives

Click here ­to­ read full press release/ article | Ref: Agile Therapeutics | Image: Agile Therapeutics